


WHAT IS CLAIMED IS:

1. A compound having formula (I), or salt thereof, wherein



Ring B is a 5-membered heterocycle having 1-2 heteroatoms selected from N, S, and O, and substituted with 0-2 C₁₋₂ alkyl groups;

R¹ is C₁₋₆ alkyl, C₁₋₆ haloalkyl, or C₁₋₆ deuterioalkyl;

R² is C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₀₋₆ alkyl-C₆₋₁₀ aryl, C₀₋₆ alkyl-C₃₋₆ cycloalkyl, or a C₀₋₆ alkyl-3 to 6 membered heterocycle having 1-4 heteroatoms selected from N, S and O, wherein any of the aryl, cycloalkyl, or heterocycle groups are substituted with 0-3 R^{2a}, and wherein any of the alkyl groups are substituted with 0-1 OH;

R^{2a} is halo, CN, =O, C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy-C₁₋₆ alkoxy, C₁₋₆ deuterioalkyl, C₁₋₆ deuterioalkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₀₋₃ alkyl-C₃₋₆ cycloalkyl-C₀₋₃ alkyl-, C₃₋₆ halocycloalkyl, C₃₋₆ cycloalkoxy, C₃₋₆ cycloalkyl-C₁₋₆ alkoxy-, C₃₋₆ cycloalkyl-C₁₋₃ deuterioalkoxy-, C₃₋₆ cycloalkyl-C₁₋₃ haloalkoxy-, C₁₋₆ alkoxy-C₁₋₃ alkyl-, C₃₋₆ cycloalkoxy-C₁₋₃ alkyl-, C₆₋₁₀ aryl, phenyl-C₁₋₃ alkoxy-, C₆₋₁₀ aryl-O-, phenyl C₁₋₄ alkyl-SO₂-, C₁₋₄ alkyl-SO₂-, C₃₋₆ cycloalkyl-SO₂-, NR³R³CO-, NR³R³-(CH₂)_n-, R⁴-C(O)-, R⁴-OC(O)-, R⁴-C(O)O-, R³-NH-C(O)O-, R⁵-OC(O)NH-, R³-NH-C(O)NR³-, R⁵-SO₂-, R⁴-SO₂NH-, R⁴-NHSO₂-, heterocycle-, wherein each heterocycle is independently a 4-6 membered ring having 1-2 heteroatoms selected from N and O, and wherein each alkyl, cycloalkyl, aryl, phenyl, or heterocycle are substituted with 0-2 R^{2b};

R^{2b}, at each occurrence, is independently OH, C₁₋₃ alkyl, C₁₋₃ alkoxy, hydroxy C₁₋₃ alkyl, hydroxy C₁₋₃ alkoxy, halo, C=O, C₁₋₃ haloalkyl, or C₁₋₃ haloalkoxy;

R³ is, independently at each occurrence, H, C₁₋₆ alkyl, C₀₋₃ alkyl-C₃₋₆ cycloalkyl, C₀₋₃ alkyl-phenyl;

R⁴ is, independently at each occurrence, H, C₁₋₆ alkyl, C₀₋₃ alkyl-C₃₋₆ cycloalkyl, C₀₋₃ alkyl-phenyl or C₁₋₆ haloalkyl;

R⁵ is, independently at each occurrence, C₁₋₆ alkyl, C₀₋₃ alkyl-C₃₋₆ cycloalkyl, C₀₋₃ alkyl-phenyl; and

n is 0, 1 or 2.

2. A compound of claim 1, or salt thereof, wherein

Ring B is thiophenyl, thiazolyl, imidazolyl, or pyrazolyl, any of which are substituted with 0-2 C₁₋₃ alkyl.

3. A compound of claims 1-2, or salt thereof, wherein

R² is C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₀₋₃ alkyl-phenyl, C₀₋₃ alkyl-C₃₋₆ cycloalkyl, or a C₀₋₃ alkyl-5 to 6 membered heterocycle, wherein the heterocycle is selected from pyridinyl or pyrrolyl, wherein any of the phenyl, cycloalkyl, or heterocycle groups are substituted with 0-3 R^{2a}, and wherein any of the alkyl are substituted with 0-1 OH.

4. A compound of claims 1-3, or salt thereof, wherein

R^{2a} is halo, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy or C₃₋₆ cycloalkyl-C₁₋₃ alkoxy-.


5. A compound of claims 1-5, or salt thereof, wherein

R² is C₁₋₄ alkyl-phenyl, substituted with 0-3 R^{2a}.

6. A compound of claims 1-5, or salt thereof, wherein


R^{2a} is halo, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, or C₁₋₆ haloalkoxy.

7. A compound of claims 1-6, or salt thereof, wherein B is,



, any of which may be substituted with 0-2 C₁₋₂ alkyl groups.

8. A compound of claims 1-6, or salt thereof, wherein B is,



9. A compound of claim 1, or salt thereof, wherein the compound is selected from the examples.

10. A pharmaceutical composition comprising one or more compounds of claims 1-9, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

11. A method of inhibiting casein kinase RIPK1 activity in a patient, comprising administering to the patient in need thereof, a therapeutically effective amount of one or more compounds according to claims 1-9.

12. A method for treating a disease comprising the administration to a subject in need thereof a therapeutically effective amount of at least one of claims 11, wherein the disease is selected from inflammatory bowel disease, ulcerative colitis, Crohn's disease, psoriasis, rheumatoid arthritis (RA), and heart failure.